2890. Pharmacokinetics, Safety, and Efficacy of Ceftazidime-Avibactam in Neonates and Young Infants with Bacterial Infections: Results from a Phase 2a, 2-part, Open-label, Non-randomized, Multicenter Trial

BACKGROUND: Antibiotic resistance in pediatrics, including neonates and infants, is increasing globally. Ceftazidime-avibactam (CAZ-AVI) is approved for use in pediatric patients (age ≥ 3 months) with Gram-negative bacterial infections. This study evaluated pharmacokinetics (PK), safety, and efficac...

Descripción completa

Detalles Bibliográficos
Autores principales: Bradley, John S, Roilides, Emmanuel, England, Richard, Tawadrous, Margaret, Yan, Jean, Soto, Elena, Stone, Gregory, Kamat, Shweta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678973/
http://dx.doi.org/10.1093/ofid/ofad500.2473

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678973/
http://dx.doi.org/10.1093/ofid/ofad500.2473

Ejemplares similares